Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
November 18, 2021
Revance to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 10, 2021
Revance to Participate in the Stifel 2021 Virtual Healthcare Conference
November 9, 2021
Revance Reports Third Quarter 2021 Financial Results, Provides Corporate Update
November 2, 2021
Revance to Release Third Quarter 2021 Financial Results on Tuesday, November 9, 2021
October 15, 2021
Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines
October 12, 2021
Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021
October 11, 2021
Revance Announces the Launch of OPUL™, the First-of-its-Kind Relational Commerce Platform for Aesthetic Practices
September 16, 2021
Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021
September 10, 2021
Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting
September 2, 2021
Revance to Participate in the Wells Fargo Securities Healthcare Conference
Displaying 41 - 50 of 305